SCHEMBL1839958

SCHEMBL1839958

Nc1nccc(-c2c[nH]c3nccc(N4C[C@@H](N)[C@H](O)C4)c23)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 8/20 0.54
CDK9 P50750 8/20 0.54
CDK5 Q00535 8/20 0.54
CDK5R1 Q15078 8/20 0.54
CDK2 P24941 8/20 0.54
CCNA2 P20248 7/20 0.54
CCNA1 P78396 7/20 0.54
ROCK1 Q13464 11/20 0.52
CDC42BPB Q9Y5S2 11/20 0.52
ROCK2 O75116 10/20 0.51
CDK1 P06493 2/20 0.47
PDPK1 O15530 2/20 0.46
CCNB2 O95067 1/20 0.44
HTR1A P08908 1/20 0.44
CCNB1 P14635 1/20 0.44
PRKACA P17612 1/20 0.44
PRKACG P22612 1/20 0.44
PRKACB P22694 1/20 0.44
HTR2B P41595 1/20 0.44
GSK3B P49841 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1839927 0.93 CDK2 (0.58) CCNT1CDK9CDK5CDK5R1CDK2
SCHEMBL1841314 0.93 CDK2 (0.58) CCNT1CDK9CDK5CDK5R1CDK2
SCHEMBL1839267 0.93 CDK2 (0.58) CCNT1CDK9CDK5CDK5R1CDK2
SCHEMBL1839965 0.91 ROCK1 (0.60) CCNT1CDK9CDK5CDK5R1CDK2
SCHEMBL12347383 0.91 ROCK1 (0.60) CCNT1CDK9CDK5CDK5R1CDK2
SCHEMBL1839245 0.91 ROCK1 (0.57) CCNT1CDK9CDK5CDK5R1CDK2
SCHEMBL1842447 0.90 CDK2 (0.57) CCNT1CDK9CDK5CDK5R1CDK2
SCHEMBL12346737 0.88 CCNT1 (0.53) CCNT1CDK9CDK5CDK5R1CDK2
SCHEMBL1840009 0.88 CCNT1 (0.53) CCNT1CDK9CDK5CDK5R1CDK2
SCHEMBL12346713 0.87 CCNT1 (0.53) CCNT1CDK9CDK5CDK5R1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A 2011-10-20 JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 CCNT1 25/4885CDK9 6/4885CDK5 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.